The hottest Drug Development Substack posts right now

And their main takeaways
Category
Top Science Topics

Ensitrelvir (Xocova®): Japanese Company Shionogi & Co., Ltd. Sets a Model for Success in Translational Research for the Coming Future of Ethical Science

Popular Rationalism • 455 implied HN points • 29 Oct 24
🏥 Health Politics Drug Development
  1. Ensitrelvir, also known as Xocova, is a new antiviral pill that is 30 times more effective than a placebo. It was developed by a Japanese company called Shionogi & Co., which worked closely with researchers.
  2. This medication targets a key enzyme the virus needs to replicate, making it effective against COVID-19 symptoms, especially those caused by Omicron variants. It has shown a strong safety profile and fewer side effects compared to some other treatments.
  3. Xocova is easier to take than some alternatives because it requires only a once-daily dose and has fewer interactions with other medications. This makes it a more convenient option for many patients.

How to Design Antibodies

Asimov Press • 754 implied HN points • 11 Mar 26
🔬 Science Drug Development
  1. AI models now let researchers design antibody binders on the computer, greatly reducing the experimental search effort needed to find promising candidates.
  2. There is a practical five-step pipeline — pick a target, prepare or predict its structure, run design tools, filter candidates, and validate in the lab — which uses public tools but typically costs thousands of dollars.
  3. Design success is highly target-dependent and improving affinity, specificity, and drug-like properties remains difficult and costly, but AI makes it realistic to engineer more complex, multi-property binders going forward.

Exenatide - the drug that failed

Rory’s Always On Newsletter • 595 implied HN points • 18 Oct 24
🏥 Health Politics Drug Development
  1. Exenatide, a drug initially hopeful for slowing Parkinson's, failed in its final trial. This has left many in the Parkinson's community feeling uncertain and disappointed.
  2. Researchers are still figuring out why the drug worked in earlier tests but failed later. They need more data to understand if it was because the drug didn't reach the brain or if it just wasn't effective.
  3. The failure of Exenatide could make it harder for other similar drugs to get funding for trials. Meanwhile, experts emphasize that exercise remains a reliable way to manage Parkinson's symptoms.

AI Won't Automatically Accelerate Clinical Trials

Asimov Press • 786 implied HN points • 27 Feb 26
🏥 Health Politics Drug Development
  1. Better AI-designed molecules won't automatically make clinical trials faster, because timelines are set by human biology, patient recruitment, logistics, and regulatory processes that take real calendar time.
  2. Clinical trials do two jobs—validation and learning—and AI needs rich human trial data to improve; many important outcomes, especially for chronic diseases and aging, take years to observe so trials remain slow even with better drugs.
  3. Real acceleration requires institutional and regulatory reforms—like validated surrogate endpoints, streamlined review pathways, and better data sharing—because AI alone can only improve trials at the margins until those systems change.

Beyond Magic Bullets: Alzheimer’s Needs the Right Cocktail and Timing

Brain Pizza • 331 implied HN points • 17 Jan 26
🔬 Science Drug Development
  1. Alzheimer's will likely need a combination of therapies instead of a single 'magic bullet' drug.
  2. Recent results—modest GLP‑1 signals, negative phase 3 trials, and limited amyloid drug benefits—suggest single agents aren't enough and that the timing of interventions matters.
  3. Immune strategies such as an Alzheimer's vaccine could be an important component of a multi-pronged treatment plan when used at the right disease stage.
Get a weekly roundup of the best Substack posts, by hacker news affinity:

Clinic-in-the-Loop

Asimov Press • 567 implied HN points • 29 Dec 25
🔬 Science Drug Development
  1. Clinical trials should be treated as active engines of discovery, not just a final yes/no test; faster, more frequent trials create feedback loops that turn clinical data into better drug designs.
  2. The CAR‑T story shows that small, information‑rich human studies can reveal why early designs fail and guide specific fixes that lead to major breakthroughs.
  3. Regulatory, manufacturing, and institutional barriers make these learning‑focused trials slow and costly, so policy and technical changes are needed to lower barriers, enable adaptive development, and collect richer in‑human measurements.

Medical Roundup #4

Don't Worry About the Vase • 1747 implied HN points • 18 Feb 25
🏥 Health Politics Drug Development
  1. Medical news has slowed down as other topics grab our attention, but real developments are happening quickly due to advancements in AI.
  2. Life expectancy is on the rise in many countries, and we are seeing breakthroughs in preventative healthcare and treatment options, like effective ways to prevent HIV.
  3. It is important to be cautious and proactive about your health. Sometimes doctors may not give the full picture, so getting a second opinion can make a difference.

Hub-and-Spoke Biotechs: Nimbus Therapeutics

The Century of Biology • 354 implied HN points • 20 Oct 24
đź’Ľ Business Drug Development
  1. Nimbus Therapeutics uses a unique hub-and-spoke model to develop drugs. This lets them separate the main company from individual drug projects, so they can sell successful drugs while keeping the main business intact.
  2. The company focuses on computational drug discovery to make the process faster and cheaper. By using advanced technology, they can predict which drugs might succeed before doing expensive experiments.
  3. Nimbus has successfully sold several drug assets, demonstrating the effectiveness of their model. They show that a biotech can grow and make money while being flexible and innovative.

Making a “Miracle” HIV Medicine

Asimov Press • 206 implied HN points • 23 Feb 25
🏥 Health Politics Drug Development
  1. Lenacapavir is a new injectable drug that can prevent HIV for up to six months, showing a higher effectiveness than daily pills.
  2. The drug is being offered at reduced prices in many low-income countries, but there are concerns about access and affordability in some regions.
  3. Despite its promise, lenacapavir's future depends on getting it to those who need it, especially given changes in government funding for HIV prevention programs.

Alexander Shulgin's Greatest Psychedelic Hits

Tripsitter • 119 implied HN points • 26 Jun 23
🏥 Health & Wellness Drug Development
  1. Alexander Shulgin, known as 'the godfather of psychedelics,' created hundreds of psychedelic compounds, with 6 standing out as his favorites, named the 'magical half-dozen.'
  2. Shulgin's work revolutionized the field of designer drugs and led to the exploration of thousands of psychoactive substances.
  3. Shulgin's approach to testing new compounds was meticulous, starting with low doses and gradually increasing, emphasizing safety and understanding the threshold dose for each substance.

The first non-opioid painkiller

The Works in Progress Newsletter • 34 implied HN points • 26 Jun 25
🏥 Health & Wellness Drug Development
  1. Journavx is the first non-opioid pain reliever approved by the FDA, aiming to reduce reliance on addictive opioids for pain management. It works by blocking specific sodium channels in pain-sensing neurons instead of acting on the brain, which helps avoid side effects linked to opioids.
  2. The development of Journavx took decades due to the complex nature of pain and the challenges in finding effective, non-addictive alternatives. Researchers faced multiple setbacks and failures before finally succeeding with this novel painkiller.
  3. Currently, Journavx is mainly effective for treating acute pain and isn't yet approved for chronic pain conditions. It offers a new option for patients needing pain relief, especially in situations where traditional medications aren't sufficient.

Edge 442: If You Thought DeepMind's AlphaFold was Impressive, Wait Until You Learn About AlphaProteo

TheSequence • 77 implied HN points • 24 Oct 24
đź•ą Technology Drug Development
  1. DeepMind has developed a new AI model called AlphaProteo, which focuses on designing proteins that can interact with specific targets. This is important for advancing drug development.
  2. Proteins are crucial for many biological processes and their interactions can be manipulated for various applications, such as treating diseases or improving diagnostics.
  3. With AlphaProteo, scientists can create protein binders that may help block harmful interactions in the body, leading to better therapies and health outcomes.

Weekly Dose of Optimism #79

Not Boring by Packy McCormick • 94 implied HN points • 02 Feb 24
🔬 Science Drug Development
  1. Biden administration to offer a $1.5 billion loan to restart a Michigan nuclear power plant, signaling support for the nuclear industry.
  2. Nat Bullard's Decarbonization presentation highlights climate change challenges, renewable energy growth, and investment opportunities in clean tech.
  3. Elon Musk's Neuralink achieves a milestone by implanting a brain interface, potentially advancing cognitive abilities and treating neurological disorders.

A Dormant Army Within

Holodoxa • 2 HN points • 03 Jul 24
🏥 Health & Wellness Drug Development
  1. The immune system has key components like T cells which play a crucial role in fighting cancer by harnessing latent immunity.
  2. Researchers like James Allison and Tasuku Honjo have made significant contributions in understanding how cancer evades the immune system and how immune checkpoints like CTLA-4 and PD-1 can be targeted to enhance immune response against cancer.
  3. Cellular immunotherapy, particularly immune checkpoint inhibitors targeting PD-(L)1, has shown great potential in treating various cancers, with some patients showing long-term remissions and ongoing innovative developments in this field.

Virtual Screening for New Antibiotics: A Machine Learning Approach to LpxC Inhibition

LatchBio • 20 implied HN points • 12 Nov 24
🔬 Science Drug Development
  1. Antibiotic resistance is a big problem, and many drug companies are not making new antibiotics anymore. Machine learning can help find new antibiotics by quickly searching through lots of compounds.
  2. In a study, researchers looked at 250,000 chemical compounds to find potential antibiotics that target a specific enzyme in harmful bacteria. This shows how technology can speed up the drug discovery process.
  3. Finding new antibiotics is really important for health, especially as bacteria become more resistant. Using advanced tools to identify promising compounds could save time and money in developing new treatments.

How does arthritis actually work?

LatchBio • 12 implied HN points • 20 Jan 25
🏥 Health & Wellness Drug Development
  1. Arthritis isn't just one disease; it's a group of conditions that cause joint pain and inflammation, with osteoarthritis being the most common type. It can affect a lot of people, and understanding the differences is key to treatment.
  2. There's a specific type of T cell that gets stuck in arthritic joints and seems to play a big role in causing inflammation. These T cells don’t directly cause pain but help other immune cells trigger the symptoms.
  3. Current treatments for arthritis focus on reducing inflammation but don't eliminate the root cause. New research suggests targeting the stuck T cells and their signaling could lead to better, more lasting treatments.

Tune Therapeutics

Axial • 37 implied HN points • 22 Oct 23
🏥 Health & Wellness Drug Development
  1. Axial partners with inventors and invests in early-stage life sciences companies.
  2. Tune Therapeutics focuses on genetic tuning for controlling gene expression without DNA alteration.
  3. Genetic tuning by Tune Therapeutics may enable treating complex diseases more precisely.

Tectonic Therapeutic: Protein Engineering and Fc-relaxin for Hypertension

Axial • 7 implied HN points • 31 Jan 25
🏥 Health & Wellness Drug Development
  1. Tectonic Therapeutic focuses on protein engineering to help treat hypertension. This means they are working on new medical treatments using proteins to effectively lower blood pressure.
  2. Axial invests in early-stage life sciences companies. They are particularly interested in supporting new ideas and inventions that can grow to make a big impact in healthcare.
  3. Support for inventors is a key part of Axial's mission. They aim to help those who are passionate about creating lasting solutions in the life sciences field.

Axial Discovery - Kidney disease

Axial • 29 implied HN points • 06 Mar 23
🏥 Health & Wellness Drug Development
  1. Over 30 million people in the US are affected by kidney disease, leading to high healthcare costs and lowered quality of life.
  2. New tools like genomics, proteomics, and metabolomics are transforming drug development for kidney diseases.
  3. Companies like Goldfinch Bio and Chinook Therapeutics are developing medicines for rare kidney diseases with defined clinical milestones.

Roche's neurology strategy

Axial • 7 implied HN points • 13 Mar 24
🏥 Health & Wellness Drug Development
  1. Roche is focusing on developing therapies for neurological diseases like Alzheimer's, with a new drug called trontinemab showing potential for rapid clearance of amyloid plaques in the brain.
  2. Roche's neurology strategy includes a diverse pipeline of treatments for various conditions like multiple sclerosis, neuromuscular disorders, and gene therapies for muscle-related illnesses.
  3. The company's commitment to Alzheimer's research is driven by the amyloid hypothesis, societal impact, and economic burden, aiming to improve patient outcomes and address the growing need for effective treatments in the aging population.

MoonLake Immunotherapeutics

Axial • 7 implied HN points • 17 Feb 24
🏥 Health & Wellness Drug Development
  1. MoonLake Immunotherapeutics is developing a tri-specific nanobody therapy called Sonelokimab (SLK) that has shown significant efficacy in treating inflammatory diseases like HS, PsA, and PsO.
  2. SLK offers unique benefits like blocking all IL-17 pro-inflammatory dimers, enabling tissue penetration, and maintaining high response rates in patients with moderate-to-severe conditions.
  3. MoonLake's SLK has the potential to become a best-in-class IL-17 inhibitor in a multibillion-dollar market, with its innovative structure, clinical success, and competitive advantages over existing treatments.

Axial Discovery - Phenotypic screening

Discovery by Axial • 3 implied HN points • 27 Mar 23
🔬 Science Drug Development
  1. Phenotypic screening focuses on identifying specific physical or biochemical traits of interest for drug discovery.
  2. Key rules for effective phenotypic screens include selecting relevant cell models, designing disease-specific assays, and defining clinical-like endpoints.
  3. Advancing phenotypic screening requires improving throughput of complex models, developing translational disease models, enhancing proteomic tools, and integrating phenotypic and target-based screening.